Ertumaxomab

Ertumaxomab
Monoclonal antibody
Type	Trifunctional antibody
Source	Rat/mouse hybrid
Target	HER2/neu, CD3
Clinical data
Trade names	Rexomun
ATC code	none;
Identifiers
CAS Number	509077-99-0 ;
ChemSpider	none;
UNII	L5L45YGP1O;
	(what is this?) (verify)

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.^[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.^[2] (So they could concentrate on their other product catumaxomab (trade name Removab).^[3]^: 35)

References

^ Fresenius
^ ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
^ "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Fresenius

[2] ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

[3] "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.

[1]

[2]

[3]